MedTrace Logo

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

NCT00027690 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2019-07-23

No results posted yet for this study

Summary

Phase II trial to study the effectiveness of gefitinib in treating patients who have persistent or recurrent endometrial cancer. Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of endometrial cancer.

Conditions

  • Recurrent Uterine Corpus Carcinoma

Interventions

DRUG

Gefitinib

Given orally

OTHER

Laboratory Biomarker Analysis

Correlative studies

Sponsors & Collaborators

  • Gynecologic Oncology Group

    collaborator NETWORK

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Kimberly Leslie · Gynecologic Oncology Group

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Primary Completion
2004-09-30
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00027690 on ClinicalTrials.gov